SCHEMBL30545331

SCHEMBL30545331

Cc1cc(B2OC(C)(C)C(C)(C)O2)ccc1[C@@H]1CO[C@@H](C)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.40
BACE1 P56817 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
AAK1 Q2M2I8 2/20 0.36
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
NR1H2 P55055 4/20 0.33
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
CNR1 P21554 1/20 0.31
GRM5 P41594 1/20 0.31
HIF1A Q16665 2/20 0.31
LMNA P02545 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ROCK1 Q13464 1/20 0.31
NR1H3 Q13133 3/20 0.30
DGAT1 O75907 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30545334 1.00 USP30 (0.40) USP30BACE1BACE2AAK1PRMT5
SCHEMBL25333411 0.86 LIPG (0.34) BACE1BACE2CYP3A4HIF1AROCK1
SCHEMBL25331468 0.86 LIPG (0.34) BACE1BACE2CYP3A4HIF1AROCK1
SCHEMBL30545426 0.85 USP30 (0.43) USP30BACE1BACE2AAK1PRMT5
SCHEMBL30545475 0.85 USP30 (0.43) USP30BACE1BACE2AAK1PRMT5
SCHEMBL30545570 0.85 USP30 (0.43) USP30BACE1BACE2AAK1PRMT5
SCHEMBL30545319 0.84 USP30 (0.41) USP30BACE1BACE2AAK1PRMT5
SCHEMBL21682675 0.82 USP30 (0.44) USP30BACE1BACE2PRMT5WDR77
SCHEMBL4394939 0.81 USP30 (0.48) USP30BACE1BACE2AAK1PRMT5
SCHEMBL30545468 0.81 NR1H2 (0.39) USP30NR1H2CYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2025-04-17 US disclosed
EP-4466072-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS Almac Discovery Limited (GB) 2024-11-27 EP disclosed
WO-2023139241-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, SENP7 USP30 31/4885BACE1 241/4885BACE2 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.